Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rare fat disorder may quietly fuel hidden inflammation

NCT ID NCT06107439

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de la Réunion Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are studying whether adults with Dunnigan lipodystrophy, a rare genetic condition that changes how the body stores fat, have higher levels of inflammation than people without it. The trial enrolls 64 non-diabetic adults on Reunion Island, including those with the condition and healthy controls. Participants give blood and urine samples so scientists can measure inflammatory markers and compare the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If inflammation markers run higher in people with Dunnigan lipodystrophy, doctors could one day monitor or treat that inflammation to reduce related health risks.
What could go wrong
This is a small observational study of 64 people, so it cannot prove cause and effect. Results may not apply to people with other forms of lipodystrophy or to those with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

64 people

The number who actually took part.

Started

Aug 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subject (\>18 years old) affected by partial Dunnigan lipodystrophy in the homozygous or heterozygous state (genetic search for the positive mutation carried out before inclusion in the study). * Person affiliated to or beneficiary of a social security scheme. * Free, informed and written consent signed by the participant and the investigator. Exclusion Criteria: * \- Minor * Persons placed under judicial protection, person participating in another research including a period of exclusion still in progress, severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study * Previous known diabetes * Pregnant woman * Woman who gave birth less than 6 months ago * Breastfeeding in progress * Participation in other research that may have an impact on the evaluation of the main judgment criteria * Hemoglobin b level \< 7 mg/dl or \< 9-10 mg/dl for patients with cardiovascular or respiratory pathology. * Proven inflammatory pathologies * Anti-inflammatory treatment: taking corticosteroids in the last 3 months. * Active smoking

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dunnigan syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

familial partial lipodystrophy familial partial lipodystrophy, Dunnigan type lipodystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dunnigan syndrome Lipodystrophy

Contacts and locations

Locations

  • CHU La Réunion DRCI

    Saint-Pierre, 97400, Reunion

More trials for these conditions

Other studies related to the condition(s) this trial covers.